- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02687581
Efficacy of Intermittent Occlusion Therapy Glasses for Amblyopia
This study is designed to evaluate the effectiveness of a novel amblyopia treatment - Intermittent occlusion therapy (IO-therapy) glasses (AmblyzTM) in treating severe amblyopia.
Children ages 3 to 8 years with severe amblyopia (visual acuity of 20/100 to 20/400 in the amblyopic eye) will be enrolled and randomized into two groups: 1) standard 6-hour patching group or 2) 12-hour IO-therapy glasses group.
The study also observe the effectiveness of IO-therapy glasses on two types of difficult amblyopia: deprivation amblyopia associated with congenital or developmental cataract, and myopic anisometropic amblyopia.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Children ages 3 to < 8 years with severe/dense amblyopia (visual acuity of 20/100 to 20/400 in the amblyopic eye) will be enrolled and randomized into two groups: 1) standard 6-hour patching group or 2) 12-hour IO-therapy glasses group.
Children ages 3 to < 8 years with deprivation amblyopia associated with congenital or developmental cataracts (visual acuity of 20/40 to 20/400 in the amblyopic eye) will be enrolled.
Children ages 3 to < 8 years with myopic anisometropic amblyopia will be enrolled into an intermittent occlusion therapy glasses (AmblyzTM) group.
According to visual acuity, they will receive one of two IO-therapy glasses treatment regimens: 1) If the amblyopic eye is between 20/40 to 20/80 inclusive, 4-hour IO-therapy glasses or 2) If the amblyopic eye is between 20/100 to 20/400 inclusive, the child will receive12-hour IO-therapy glasses.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Elkins Park, Pennsylvania, United States
- Salus University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 3 to < 8 years
- Amblyopia associated with strabismus, anisometropia, or both
Visual acuity, measured in each eye without cycloplegia within 7 days prior to enrollment using the ATS single-surround HOTV letter protocol as follows:
- Visual acuity in the amblyopic eye between 20/100 and 20/400 inclusive
- Visual acuity in the sound eye 20/32 or better
Spectacle correction (if applicable) for measurement of enrollment visual acuity must meet the following criteria and be based on a cycloplegic refraction within 6 months:
- Requirements for spectacle correction:
- For patients meeting criteria for only strabismus i. Hypermetropia if corrected must not be undercorrected by more than +1.50 D spherical equivalent, and the reduction in plus sphere must be symmetric in the two eyes. Otherwise, spectacle correction is at investigator discretion.
- For patients meeting criteria for anisometropia or combined-mechanism i. Spherical equivalent must be within 0.50 D of fully correcting the anisometropia ii. Hypermetropia must not be undercorrected by more than +1.50 D spherical equivalent, and reduction in plus must be symmetric in the two eyes iii. Cylinder power in both eyes must be within 0.50 D of fully correcting the astigmatism iv. Cylinder axis in the spectacle lenses in both eyes must be within 6 degrees of the axis of the cycloplegic refraction
- Wearing optimal spectacle correction for a minimum of 4 weeks at the time of enrollment.
- Gestational age > 34 weeks and birth weight > 1500 grams
- Parent willing to accept randomization
- Parent willing to be contacted and has access to phone
- Parent does not anticipate relocation outside area of active study site
Exclusion Criteria:
• Amblyopic eye has myopia worse than -3.00D spherical equivalent.
- Previous amblyopia treatment within 6 months.
- Prior intraocular or refractive surgery
- Known skin reactions to patch or bandage adhesives
- Systemic diseases that may cause reduced vision such as Down syndrome.
If patients are in the deprivation amblyopia category, the following criteria must be met for the patient to be enrolled in the study:
- Age 3 to < 8 years
- Amblyopia due to previous congenital or developmental cataract surgery.
- Visual acuity, measured in each eye without cycloplegia within 7 days prior to enrollment using the ATS single-surround HOTV letter protocol as follows:
a. Visual acuity in the amblyopic eye between 20/40 and 20/400 inclusive b. Visual acuity in the sound eye 20/32 or better c. Inter-eye acuity difference ≥ 2 logMAR lines (i.e., amblyopic eye acuity at least 3 lines worse than sound eye acuity) d) Gestational age > 34 weeks and birth weight > 1500 grams e) Parent willing to be contacted and has access to phone.
If patients are enrolled in the myopic anisometropia amblyopia category, the following criteria must be met for the patients to be enrolled in the study.
- Aged 3 to <8 years
- Best-corrected VA in the amblyopic eye of 20/40 to 20/400 inclusive
- Best-corrected VA in the fellow eye of 20/40 or better
- Magnitude of myopic anisometropia of > 3.00 D
- Intereye acuity difference of > 3 logMAR lines
- Amblyopia associated with myopic anisometropia
- Has been wearing optimal spectacle correction for a minimum of four weeks
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 12-hour IO-therapy Glasses
wear IO-therapy glasses for 12-hour
|
12-hour of 50% intermittent occlusion therapy on the fellow eye.
|
Active Comparator: 6-hour patching
wear the eye patch for 6-hour
|
6-hour of eye patch on the fellow eye
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual Acuity Improvement
Time Frame: 12± 1 weeks after treatment
|
Visual acuity was measured with ATS-HOTV methods in logMAR.
The larger amount means the worse acuity.
Visual acuity improvement is defined as the change at the primary outcome follow-up visit from the baseline.
(Note: Visual acuity improvement = Visual acuity at the baseline - Visual acuity at the 12-week follow-up) The larger amount of change indicates better improvement.
|
12± 1 weeks after treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jingyun Wang, PhD, Salus University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HJW1602
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amblyopia
-
Universitat Politècnica de CatalunyaParc Sanitari Sant Joan de Déu; Hospital Mutua de TerrassaCompletedAmblyopia | Anisometropic Amblyopia | Strabismic Amblyopia | Amblyopia Occlusion | Unilateral AmblyopiaSpain
-
Vedea Healthware BVElisabeth-TweeSteden Ziekenhuis; Jeroen Bosch Ziekenhuis; Health Holland; Oogziekenhuis... and other collaboratorsRecruitingAmblyopia | Amblyopia, Anisometropic | Amblyopia StrabismicNetherlands
-
Universitat Politècnica de CatalunyaHospital Mutua de TerrassaCompletedAmblyopia | Anisometropic Amblyopia | Strabismic AmblyopiaSpain
-
Alaska Blind Child DiscoveryCompletedStrabismus | Strabismic Amblyopia | Refractive AmblyopiaUnited States
-
Baylor College of MedicineActive, not recruitingHyperopia | High Myopia | Anisometropia | Amblyopia Isometropic | Amblyopia Bilateral | High AstigmatismUnited States
-
Medical University of ViennaRecruitingAmblyopia ex Strabismus | Amblyopia ex AnisometropiaAustria
-
National Cheng-Kung University HospitalChang Gung Memorial HospitalCompletedAmblyopia | Amblyopia, Anisometropic
-
Shahid Beheshti University of Medical SciencesUnknownThe New Treatment in Amblyopia TherapyIran, Islamic Republic of
-
University of BaselUniversity Medical Center NijmegenWithdrawnStrabismic Amblyopia
-
Wenzhou Medical UniversityUnknown
Clinical Trials on IO-therapy Glasses
-
Salus UniversityTerminated
-
Immune-Onc TherapeuticsRegeneron PharmaceuticalsActive, not recruiting
-
Jiangsu Alphamab Biopharmaceuticals Co., LtdPeking UniversityCompletedHER2-positive Solid TumorsChina
-
Immune-Onc TherapeuticsActive, not recruitingSolid Tumor, AdultUnited States
-
WellSpan HealthUniversity of PennsylvaniaCompletedDifficult Peripheral IV AccessUnited States
-
Second Affiliated Hospital, School of Medicine,...The First Affiliated Hospital with Nanjing Medical University; Shanghai Zhongshan... and other collaboratorsRecruitingOut-of-Hospital Cardiac ArrestChina
-
Indiana University School of MedicineTerminatedIntermittent ExotropiaUnited States
-
VA Office of Research and DevelopmentCompletedObstructive Sleep ApneaUnited States
-
Implandata Ophthalmic Products GmbHCompletedPrimary Open-angle GlaucomaGermany
-
The Cleveland ClinicRecruitingStrabismus | AmblyopiaUnited States